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In vitro transfection experiments have shown that cooperation between two different oncogenes can confer a fully malig- 
nant phenotype to primary rodent cells. We have previously reported that SW 613-Tul cells, derived from a tumor in- 
duced in a nude mouse by the human breast carcinoma cell line SW 613-S showed a 30-fold amplification of the c-m_rc 
gene. In the present work, we show that these cells also harbor an activated c-Ki-ras gene capable of inducing the forma- 
tion of foci upon transfection of NIH 3T3 cells with SW 613-Tul genomic DNA. Our results suggest that both the c-myc 
and c-Ki-ras oncogenes, activated by two different mechanisms, may cooperate in the full expression of the tumorigenic 
phenotype of SW 613-Tul cells. 
Breast carcinoma; Gene activation; Gene amplification; ra.7 gene; myc gene 
1. INTRODUCTION 
Activation of cellular proto-oncogenes by 
various genetic alterations is believed to play a ma- 
jor role in tumor formation and/or progression 
[l-3]. In human malignancies, proto-oncogenes 
have repeatedly been found to be altered by 
chromosome translocation, gene amplification or 
specific point mutations [l-3]. The first two 
mechanisms of activation lead to disruption in the 
regulation of expression of the gene, whereas the 
latter results in a functionally altered gene product, 
such as occurs for genes of the ~~2s family [l-3]. 
Mutations in ras genes, first unveiled by transfec- 
tion assays on NIH 3T3 cells, are now detected 
with an increased frequency in human tumors, ow- 
Correspondence address: G. Carloni, Laboratoire de Genetique 
Cellulaire, IRSC, BP no.8, 94802 Villejuif Cedex, France 
ing to the advent of the more sensitive technique of 
hybridization with specific oligonucleotide probes 
[4,51. 
In the case of human breast cancer, a highly 
polymorphic and heterogeneous group of 
neoplasias [6], several studies have reported the 
frequent occurrence of c-myc or c-erbB2/neu gene 
amplification [7-l I]. Transforming genes, as 
detected by transfection assays, have been de- 
scribed in only a few human mammary tumor cell 
lines: c-Ha-r-as in HS578T [12]; c-Ki-ras in MDA- 
MB-231 [13] and H-466B [14]; N-ras, mcf-2 and 
mcf-3 in MCF-7 [ 151. mcf-3 turned out to be the c- 
rosl gene activated during gene transfer [ 161, 
whereas mcf-2 remains to be characterized. 
Here, an activated c-Ki-ras gene was identified 
by transfection of NIH 3T3 cells with DNA from 
SW 613-Tul, a subline derived from a tumor in- 
duced in a nude mouse by the human breast car- 
cinoma cell line SW 613-S [17]. Of interest is the 
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fact that we have previously shown that the c-myc 
gene is amplified 30-fold in SW 613-Tul cells [17]. 
2. MATERIALS AND METHODS 
2.1. Cell lines 
The establishment and characterization of the SW 613-Tul 
cell line have been described [17]. PCC-4 is a mouse teratocar- 
cinema cell line, in which the c-Ki-rus gene is amplified 
lo-20-fold [18]. 
2.2. DNA transfection assay 
Total cellular DNA was prepared according to Gross-Bellard 
et al. [19]. DNA transfection was carried out by the calcium 
phosphate coprecipitation method [20], essentially as in [21]. 
Briefly, 4 x lo5 NIH 3T3 cells were seeded per Petri dish in 5 ml 
Eagle’s minimal essential medium (MEM) supplemented with 
10% newborn calf serum (Gibco). 1 day later, 20~s high-M, 
DNA coprecipitated with calcium phosphate were applied to 
each dish for 5 h and the transfection was followed by a 
glycerol shock [22]. Cultures were maintained in MEM/lO% 
calf serum with medium being changed every 3-4 days. Once 
the cell monolayers reached confluency, the serum concentra- 
tion was reduced to 5%. Morphologically transformed foci 
were scored at 14-18 days. Individual foci were picked using 
cloning glass cylinders, transferred into 24-well microplates and 
propagated under low serum selective culture conditions. 
2.3. DNA blotting 
DNA from NIH 3T3 transformants was digested with EcoRI, 
separated by horizontal electrophoresis in agarose gels, 
transferred to nitrocellulose filters and hybridized with either of 
two DNA probes radiolabeled by nick-translation: (i) human 
repetitive DNA sequences prepared by reannealing sonicated 
and denatured DNA from human cells, as described by Houck 
et al. [23]; (ii) the pKBE-2 plasmid [24] carrying the v-Ki-ras on- 
cogene from Kirsten murine sarcoma virus. Hybridizations 
were carried out for 24 h under conditions of low stringency 
(30% formamide, 0.75 M NaCl, 0.075 M Na citrate, 1 x 
Denhardt solution, 100 pg/ml of sonicated-denatured salmon 
sperm DNA, at 42°C). In the case of the human repetitive DNA 
probe, the hybridization mixture was supplemented with 
50pg/ml of denatured NIH 3T3 cell DNA. 
2.4. Immunoblotting of ras p21 protein 
Cell Iysates were prepared in Laemmli sample buffer sup- 
plemented with 5% 2-mercaptoethanol and proteins were 
separated by electrophoresis on a 15% polyacrylamide gel [25]. 
Proteins were then transferred by electrophoresis onto an 
0.22 pm nitrocellulose filter (Schleicher and Schiill), as de- 
scribed by Towbin et al. [26]. The filters were preincubated for 
3-4 h at 37°C in a blocking solution containing 3% (w/v) 
bovine serum albumin and 1% (w/v) bovine immunoglobulins 
in TNE buffer (50 mM Tris-HCI, pH 7.5, 0.15 M NaCI, 2 mM 
EDTA). Hybridization was carried out for 2 h in TNE buffer 
containing 0.1% Nonidet P40, using as a probe the rat 
B 
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Fig.1. Southern blot hybridization of EcoRI-digested DNA from NIH 3T3 transformants obtained after transfection of SW 613-Tul 
DNA. (A) Hybridization with the human repetitive DNA probe of genomic DNA from two primary transformants (lanes 1,2), NIH 
3T3 control cells (lane 3) and two secondary transformants (lanes 4.5). (B) Hybridization with the pKBE-2 probe of DNA from primary 
transformants (lanes l-5) and NIH 3T3 cells (lane 6). Lanes 4 and 5 show DNA samples from the same primary transformant at 
passage 5 and 6, respectively. Arrows indicate the position of the human c-Ki-rus gene-specific bands. 
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monoclonal antibody Y13-259 [27]. After washing, the filters 
were incubated with a biotinylated anti-rat immunoglobulin an- 
tibody, followed by peroxidase-streptavidin (Amersham). The 
specific protein bands were revealed by reacting the filters with 
a peroxidase staining solution prepared in 100 ml phosphate- 
buffered saline by adding 50 mg 4-chloro-I-naphthol 
predissolved in 1 ml ethanol and 50~1 of 30% HzOz. 
3. RESULTS 
High-M, DNA from the SW 613-Tul tumor cell 
line was tested for its transforming activity by 
transfection of NIH 3T3 cells. Morphologically 
transformed foci appeared 2 weeks later with an 
efficiency of 0.055 focus/pg DNA. Each focus was 
picked, grown into mass culture and the cellular 
DNA was extracted. The DNA from these primary 
transformants was first tested by Southern blotting 
for the presence of human repetitive sequences. 
Fig. 1A (lanes 1,2) demonstrates the presence of a 
large number of DNA fragments reactive with the 
human repetitive DNA probe in the DNA of two 
such transformants, under conditions where no 
hybridization was detectable with control NIH 3T3 
DNA (lane 3). A second cycle of transfection was 
carried out with the DNA of one primary transfor- 
mant (fig. 1 A, lane 1). The transformation efficien- 
cy (0.043 focus/pg DNA) was similar to that 
observed for the first cycle of transfection. 
Analysis of the DNA from two secondary transfor- 
mants by Southern blot hybridization with the 
human repetitive DNA probe showed a set of 
defined bands (fig.lA, lanes 4,5). These results in- 
dicated that SW 613-Tul cells contained transform- 
ing sequences capable of inducing the formation of 
foci in two consecutive cycles of transfection of 
NIH 3T3 cells. 
In order to determine whether these transform- 
ing sequences corresponded to any known on- 
cogene, the DNA from several primary 
transformants induced by SW 613-Tul DNA 
transfection was analysed by Southern blotting for 
the presence of one of the genes of the ras family. 
Hybridization with probes for c-Ha-ras and N-ras 
did not detect any human-specific DNA fragment 
(not shown). In contrast, the pKBE-2 probe, con- 
taining the v-Ki-ras gene [24], detected EcoRI 
fragments of 6.7, 3.0-3.1 and 2.5 kbp, in addition 
to the endogenous mouse c-Ki-ra.s fragments, in 
the DNA of two primary transformants (fig.lB, 
lanes 1 and 4,5, respectively). No hybridization 
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was observed with the DNA of two other primary 
transformants (fig. lB, lanes 2,3), but these turned 
out to have lost the transfecting human DNA upon 
subculturing, when tested with the human 
repetitive DNA probe. The high intensity of the 
bands observed with the transformant DNA shown 
in lanes 4,5 of fig.lB is presumably due to the 
amplification of the transfected oncogene. 
Expression of the p21 ras protein in the primary 
transformants harboring the activated c-Ki-rus 
gene from SW 613-Tul was investigated by im- 
munoblotting using the broadly reactive 
monoclonal antibody Y13-259 [27]. Fig.2 (lanes 
b,c) shows that both transformants expressed 
clearly detectable amounts of p21 protein, 
although at a slightly lower level than that ex- 
pressed by the PCC4 mouse teratocarcinoma cell 
line used as a positive control (lane a) and in which 
the c-Ki-ras gene is amplified at least IO-fold [18]. 
Comparatively, the p21 ras protein band was bare- 
ly detectable in lysates from untransformed NIH 
3T3 cells (not shown). 
Our results indicate that transformation of NIH 
a b c 
Fig.2. Detection of the p21 ras protein by immunoblotting with 
the monoclonal antibody Y 13-259 in lysates from PCC4 mouse 
teratocarcinoma cells, used as a positive control (lane a) and 
from two independent primary transformants harboring the 
activated c-Ki-ras gene from SW 613.Tul (lanes b,c). The arrow 
indicates the position of the p21 ras protein band. 
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3T3 cells by transfection of SW 613-Tul DNA was 
due to a c-Ki-ras oncogene. The fact that indepen- 
dent primary transformants harbored the human 
c-Ki-ras gene indicates that transforming activity 
was not acquired during the transfection process 
but that this gene is already activated in the SW 
613-Tul cell line used as DNA donor. 
4. DISCUSSION 
We have shown here that the SW 613-Tul cell 
line harbors an activated c-Ki-ras gene, as tested by 
transfection assays on NIH 3T3 cells. The 
transforming activity of this gene is presumably 
due to a point mutation located at either codon 12, 
13 or 61, leading to an amino acid change at one 
of these positions in the encoded p21 protein. In- 
deed, all genes of the r-as family from human 
tumors active in transfection assays which have 
been analysed to date have been found to be 
altered by one of these mutations [3]. Southern 
blot analysis of Sac1 digests of primary transfor- 
mant as well as SW 613-Tul DNA (not shown) did 
not reveal the new restriction site expected to be 
present if a guanine to cytosine substitution had 
occurred at the first position of codon 12 in the ac- 
tivated c-Ki-ras gene, as described previously in the 
case of several other human tumor cell lines [28]. 
Further work is required to determine by sequence 
analysis the precise nature and location of the ac- 
tivating mutation. 
As mentioned above, the c-myc gene is amplified 
30-fold in SW 613-Tul [17]. Thus, this cell line har- 
bors two activated oncogenes, c-myc and c-Ki-rus, 
which may cooperate in the expression of the 
tumorigenic phenotype of these cells. SW 613-Tul 
was derived from a nude mouse tumor induced by 
the human breast carcinoma cell line SW 613-S 
[17]. We have recently demonstrated, by analysis 
of clonal isolates, that SW 613-S is heterogeneous 
with regard to the amplification level of the c-myc 
gene (Lavialle, C. et al., submitted). Only clones 
with a c-myc amplification level of at least 30-fold 
are capable of inducing the formation of rapidly 
growing tumors upon S.C. inoculation of nude 
mice. Once the activating mutation in the c-Ki-ras 
locus of SW 613-Tul has been identified, it will be 
of interest to investigate its presence by hybridiza- 
tion with an appropriate oligonucleotide probe in 
the genome of the parental SW 613-S cell line, as 
well as in that of the various clones derived 
therefrom. 
The coexistence of two oncogenes activated by 
different mechanisms in the same tumor cell (e.g. 
a mutated ras gene and a translocated or amplified 
c-myc gene) has been reported in some human 
hematopoietic malignant cells [29] and in some 
human solid tumors and tumor-derived cell lines 
[30,31]. This has led to speculation that con- 
secutive activation of two or more oncogenes may 
contribute to the multistep process of car- 
cinogen&is. Such a hypothesis is further supported 
by in vitro transfection experiments howing that 
two different oncogenes can cooperate in inducing 
the full malignant transformation of rodent em- 
bryo fibroblasts [32,33]. Within this context, the 
SW 613-S human breast carcinoma cell line and the 
diverse sublines derived from it, such as SW 
613-Tul, constitute an interesting experimental 
model for investigating the cooperative role of the 
two activated oncogenes c-Ki-ras and c-myc in 
tumor progression. 
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